MSD's COVID-19 Pill Molnupiravir Gains First Approval In UK
To Be Marketed As Lagevrio
Executive Summary
The UK becomes the first country to grant a marketing authorization for the oral treatment which could help cut hospitalizations and deaths by half.
You may also be interested in...
Stock Watch: Hedging The Effects Of Omicron
As well as hedging investors’ portfolios against the effects of pandemic waves, the stock prices of Pfizer and Merck & Co seem to be negatively correlated to each other, just as their pandemic-related revenues are to their traditional drug sales.
Strides Pushes Back US Expectations
Strides has pushed back US revenue guidance of $225m-$250m by a year to FY23 amid price erosion and substantial competition in the market. Meanwhile, the firm’s CEO says Merck’s molnupiravir and Pfizer’s Paxlovid are not seen impacting COVID-19 vaccine uptake as boosters and immunization for travel will drive continued demand. The Indian company expects to book Sputnik Light sales from Q4.
Roche Exit Strengthens Pfizer And Merck & Co In Covid Pill Market
Roche has bowed out of the race to develop an oral COVID-19 therapy, leaving a lucrative but likely short-lived market for its rivals.